SUPN SUPERNUS PHARMACEUTICALS, INC.

NEUTRAL Impact: 3/10 Institutional Cluster
Horizon weeks Processed 3d 17h ago
Institutional cluster: 3 buyers, 3 sellers (mixed)

Executive Summary

Institutional cluster for SUPN shows mixed activity in Q4 2025: three buyers (Wells Fargo, Morgan Stanley, Point72) added $47M in positions, while three sellers (BofA, D.E. Shaw, Two Sigma) trimmed $32.4M. The net dollar flow is slightly positive but the cluster lacks a clear directional signal due to balanced fund types and no obvious catalyst.

Key Financial Metrics

Direction
mixed
Buy Value
$169.2M
Sell Value
$99.4M
Net Flow
$14.6M

Institutional Positions

Net institutional flow: $14.6M

▲ Buyers (3)

InstitutionActionChangePosition ValueValue Δ
Wells Fargo ADD +46.2% $3.0M $1.0M
Morgan Stanley ADD +42.9% $53.6M $17.6M
Point72 ADD +28.6% $112.6M $28.4M

▼ Sellers (3)

InstitutionActionChangePrev ValueValue Δ
BofA TRIM -38.2% $40.3M -$14.4M
D.E. Shaw TRIM -27.7% $46.8M -$11.6M
Two Sigma TRIM -53.2% $12.3M -$6.3M

Actionable Insight

The lack of a dominant directional signal from this cluster suggests no imminent catalyst. Monitor SUPN's upcoming earnings for potential catalysts that could validate or reverse these positions.

Key Facts

  • Three institutional buyers added $47.0M in net new positions, led by Point72 (+$28.4M) and Morgan Stanley (+$17.6M).
  • Three institutional sellers trimmed $32.4M, led by BofA (-$14.4M) and D.E. Shaw (-$11.6M).
  • Buyers are predominantly mega-passive (Wells Fargo, Morgan Stanley) and one quant (Point72); sellers include two quants (D.E. Shaw, Two Sigma) and one mega-passive (BofA).
  • Net institutional dollar flow was +$14.6M, but the balanced number and types of funds suggest no strong conviction.

Financial Impact

Institutional activity totaled $79.4M in absolute position changes, with net buying of $14.6M.

institutional ownershipfloat turnover

Risk Factors

  • 13F data is 45+ days stale; positions may have already been unwound.
  • Selling by two quant firms (D.E. Shaw, Two Sigma) could indicate informed reduction.
  • Historical filings on SUPN have exhibited poor stock performance post-report.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-SUPN-2025-Q4
8 reports for SUPN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SUPN — sortable, filterable
Type Now
Jun 11, 2026
3d ago
Institutional Cluster
NEUTRAL ★ 3/10
$45.37 awaiting T+5awaiting T+5
May 20, 2026
25d ago
8-K
NEUTRAL ★ 3/10
$49.38 $46.85▼ −5.12%▼ −6.72%
Apr 22, 2026
7w ago
8-K
NEUTRAL ★ 2/10
$50.39 $48.55▼ −3.65%▼ −5.13%
Apr 22, 2026
7w ago
Press Release
NEUTRAL ★ 3/10
$50.39 $48.55▼ −3.65%▼ −5.13%
Apr 7, 2026
9w ago
8-K
BULLISH ★ 7/10
$51.61 $49.94▼ −3.24%▼ −6.75%
Mar 6, 2026
14w ago
Insider Cluster
NEUTRAL ★ 4/10
$53.87 $49.91▼ −7.35%▼ −5.82%
Mar 6, 2026
14w ago
Insider Cluster
NEUTRAL ★ 4/10
$53.87 $49.91▼ −7.35%▼ −5.82%
Feb 24, 2026
15w ago
8-K
BULLISH ★ 8/10
$56.32 $55.58▼ −1.31%▼ −0.21%
Showing 8 of 8

US Market Status

Market Closed — Opens in 3h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access